drugset / Trial / NCT06401603
A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To find the recommended doses of lisaftoclax and olverembatinib that can be given in combination with decitabine to participants with advanced CML and Ph+ AML.
Timeline
- Start
- 2024-08-06
- Primary completion
- 2027-01-01
- Completion
- 2029-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Listaftoclax | Unknown | — | Oral |
| Subject | Olverembatinib | Small molecule | — | Oral |
| Background | Decitabine | Small molecule | — | Intravenous |